Cti Biopharm Corp. (CTIC) 0.39 $CTIC
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)
CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis
PR Newswire - Mon Aug 29, 5:00AM CDT
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for the treatment of patients with myelofibrosis whose platelet counts are less than 100,000 per microliter -- a patient population with high-risk advanced disease. Three hundred eleven (311) patients were enrolled in the study, which formed the basis for the safety analysis. Two hundred twenty-one (221) patients who had a chance to reach Week 24 (the primary analysis time point) at the time the clinical hold was imposed and constituted the intent-to-treat (ITT) analysis population utilized for the evaluation of efficacy. Preliminary results demonstrated that the PERSIST-2 trial met one of the co-primary endpoints showing a statistically significant response rate in spleen volume reduction (SVR) in patients with myelofibrosis treated with pacritinib compared to BAT, including the approved JAK2 inhibitor ruxolitinib (p<0.01). Although the PERSIST-2 trial did not meet the other co-primary endpoint of greater than 50 percent reduction in Total Symptom Score (TSS), the preliminary analysis approached marginal significance compared to BAT (p=0.0791).
CTIC: 0.39 (unch)
CTI BioPharma Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:01PM CDT
CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the second quarter ended June 30, 2016.
CTIC: 0.39 (unch)
Surging Earnings Estimates Signal Good News for CTI BioPharma (CTIC)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 7:32AM CDT
CTI BioPharma (CTIC) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
CTIC: 0.39 (unch)
Should CTI BioPharma (CTIC) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:08AM CDT
CTI BioPharma has actually seen rising estimates over the past one month and looks well positioned for a solid gain, but has been overlooked by investors.
CTIC: 0.39 (unch)
Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting
PR Newswire - Tue Jun 07, 12:30AM CDT
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors (BAT), in patients with myelofibrosis. As previously reported, the PERSIST-1 trial met its primary endpoint in the intent-to-treat population with statistically significant reduction in spleen volume when compared to patients receiving BAT. The results represent an update on the efficacy and safety for all patients regardless of their initial platelet count, including patients with very low platelet counts at study entry, a condition known as severe or life-threatening thrombocytopenia. The most frequently occurring adverse events with pacritinib were gastrointestinal events and incidence decreased over time. For patients crossing over to receive pacritinib treatment (84 percent of BAT patients), less than 5 percent of patients had diarrhea with only one patient experiencing grade 3. Patients in the BAT arm that crossed over to receive pacritinib treatment had a similar rate of events as patients initially randomized to BAT or pacritinib. A planned analysis of the study up to 72 weeks demonstrated treatment with pacritinib led to durable reductions in spleen volume and symptom burden, two key measures of disease control, in patients with myelofibrosis, including patients with low platelets at baseline (less than 50,000 per microliter and less than 100,000 per microliter). Patients who crossed over to pacritinib from BAT experienced similar reductions in spleen volume and symptom burden as patients initially randomized to pacritinib, including patients with low platelets. Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, which are kinases found to be involved in the growth and spread of myelofibrosis and other blood-related cancers.
CTIC: 0.39 (unch)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 1.34 (-0.02), SNTA: 0.34 (+0.07), CTIC: 0.39 (unch), LPTN: 2.35 (-0.02)
CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting
PR Newswire - Thu May 19, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow up data from the Phase 3 PERSIST-1 clinical trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3-7 in Chicago, IL. The abstracts are available on the ASCO website at www.asco.org. Details regarding the poster presentations, which will include additional data not available in the abstracts, follow.
CTIC: 0.39 (unch)
Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment
PR Newswire - Wed Apr 20, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be effective in reducing survival of myelofibrosis and acute myeloid leukemia (AML) repopulating cells. Further, this study also demonstrated that the combination of pacritinib at low nanomolar concentrations with dasatinib may eliminate self-renewing leukemia stem cells in blast crisis of chronic myeloid leukemia (CML) with minimal toxicity toward normal progenitors. In myeloid leukemias, these leukemic stem cells can evade initial treatment and hide within the bone marrow microenvironment, develop resistance to current therapies, self-renew and eventually cause relapse.
CTIC: 0.39 (unch)
SHAREHOLDER NOTICE: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important April 11, 2016 Deadline in Class Action - CTIC
GlobeNewswire - Fri Apr 08, 5:30PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp. securities (NASDAQ:CTIC) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with CTI BioPharma's September 24, 2015 Public Offering (the "offering"
and/or from March 4, 2014 through February 9, 2016, inclusive (the "Class Period" of the important April 11, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for CTI BioPharma investors under the federal securities laws.
CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline - CTIC
ACCESSWIRE - Fri Apr 08, 11:54AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company" (NASDAQ: CTIC) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 16-cv-00216, is on behalf of a class consisting of all persons or entities who purchased CTI BioPharma securities: (1) pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's public offering on or about September 24, 2015 (the "Offering"; and/or (2) between March 4, 2014 and February 9, 2016, inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act".
CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Imminent Lead Plaintiff Deadline
ACCESSWIRE - Fri Apr 08, 10:21AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CTI BioPharma Corp. ("CTI" or the "Company" (NASDAQ: CTIC) of the April 11, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
CTIC: 0.39 (unch)
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016
ACCESSWIRE - Fri Apr 08, 9:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against CTI BioPharma Corp. ("CTI" or the "Company" (NASDAQ: CTIC). The class action has been filed in the United States District Court, Western District of Washington on behalf of a class consisting of all persons or entities who purchased CTI BioPharma securities: (1) pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's public offering on or about September 24, 2015 (the "Offering"; and/or (2) between March 4, 2014 and February 9, 2016, inclusive (the "Class Period".
CTIC: 0.39 (unch)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action and a Lead Plaintiff Deadline of April 11, 2016
BusinessWire - Thu Apr 07, 11:13AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CTIC: 0.39 (unch)
April 11 Deadline Alert: GPM Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Lawsuit against CTI BioPharma Corp. and Encourages Investors to Contact the Firm
BusinessWire - Wed Apr 06, 9:30AM CDT
Glancy Prongay & Murray LLP ("GPM" reminds investors of the upcoming April 11, 2016 deadline to file a lead plaintiff motion in the class action filed by GPM on behalf of a class (the "Class" of investors who purchased or otherwise acquired CTI BioPharma Corp. ("CTI BioPharma" or the "Company" (NASDAQ: CTIC) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's public offering on or about September 24, 2015 (the "Offering"; and/or (2) between March 4, 2014 and February 9, 2016, inclusive (the "Class Period). Investors who suffered losses over $50,000 on their investment in CTI BioPharma securities are encouraged to contact GPM to discuss their legal rights in this class action.
CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against CTI BioPharma Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Apr 06, 4:45AM CDT
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company" (Nasdaq: CTIC) concerning possible violations of federal securities laws between March 4, 2014 and February 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the April 11, 2016, lead plaintiff motion deadline.
CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Lead Plaintiff Deadline
PR Newswire - Tue Apr 05, 1:53PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CTI BioPharma Corp. ("CTI" or the "Company" (NASDAQ:CTIC) of the April 11, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
CTIC: 0.39 (unch)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against CTI BioPharma Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Tue Apr 05, 12:49PM CDT
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company" (Nasdaq: CTIC) concerning possible violations of federal securities laws between March 4, 2014 and February 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the April 11, 2016, lead plaintiff motion deadline.
CTIC: 0.39 (unch)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2016 -- CTIC
Marketwired - Mon Apr 04, 9:47AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2016 - CTIC
GlobeNewswire - Thu Mar 31, 1:23PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CTIC: 0.39 (unch)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)
CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis
PR Newswire - Mon Aug 29, 5:00AM CDT
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced top-line results from PERSIST-2, a randomized, controlled Phase 3 clinical trial comparing pacritinib, an investigational oral multikinase inhibitor, with physician-specified best available therapy (BAT), including ruxolitinib, for the treatment of patients with myelofibrosis whose platelet counts are less than 100,000 per microliter -- a patient population with high-risk advanced disease. Three hundred eleven (311) patients were enrolled in the study, which formed the basis for the safety analysis. Two hundred twenty-one (221) patients who had a chance to reach Week 24 (the primary analysis time point) at the time the clinical hold was imposed and constituted the intent-to-treat (ITT) analysis population utilized for the evaluation of efficacy. Preliminary results demonstrated that the PERSIST-2 trial met one of the co-primary endpoints showing a statistically significant response rate in spleen volume reduction (SVR) in patients with myelofibrosis treated with pacritinib compared to BAT, including the approved JAK2 inhibitor ruxolitinib (p<0.01). Although the PERSIST-2 trial did not meet the other co-primary endpoint of greater than 50 percent reduction in Total Symptom Score (TSS), the preliminary analysis approached marginal significance compared to BAT (p=0.0791).
CTIC: 0.39 (unch)
CTI BioPharma Reports Second Quarter 2016 Financial Results
PR Newswire - Thu Aug 04, 3:01PM CDT
CTI BioPharma Corp. (NASDAQ and MTA:CTIC) today reported financial results for the second quarter ended June 30, 2016.
CTIC: 0.39 (unch)
Surging Earnings Estimates Signal Good News for CTI BioPharma (CTIC)
Zacks Equity Research - Zacks Investment Research - Fri Jun 10, 7:32AM CDT
CTI BioPharma (CTIC) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
CTIC: 0.39 (unch)
Should CTI BioPharma (CTIC) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 7:08AM CDT
CTI BioPharma has actually seen rising estimates over the past one month and looks well positioned for a solid gain, but has been overlooked by investors.
CTIC: 0.39 (unch)
Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting
PR Newswire - Tue Jun 07, 12:30AM CDT
CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors (BAT), in patients with myelofibrosis. As previously reported, the PERSIST-1 trial met its primary endpoint in the intent-to-treat population with statistically significant reduction in spleen volume when compared to patients receiving BAT. The results represent an update on the efficacy and safety for all patients regardless of their initial platelet count, including patients with very low platelet counts at study entry, a condition known as severe or life-threatening thrombocytopenia. The most frequently occurring adverse events with pacritinib were gastrointestinal events and incidence decreased over time. For patients crossing over to receive pacritinib treatment (84 percent of BAT patients), less than 5 percent of patients had diarrhea with only one patient experiencing grade 3. Patients in the BAT arm that crossed over to receive pacritinib treatment had a similar rate of events as patients initially randomized to BAT or pacritinib. A planned analysis of the study up to 72 weeks demonstrated treatment with pacritinib led to durable reductions in spleen volume and symptom burden, two key measures of disease control, in patients with myelofibrosis, including patients with low platelets at baseline (less than 50,000 per microliter and less than 100,000 per microliter). Patients who crossed over to pacritinib from BAT experienced similar reductions in spleen volume and symptom burden as patients initially randomized to pacritinib, including patients with low platelets. Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, which are kinases found to be involved in the growth and spread of myelofibrosis and other blood-related cancers.
CTIC: 0.39 (unch)
Why Biotech Stocks Fascinate Investors? - Synta Pharma, CTI BioPharma, Lpath, and Heat Biologics
PR Newswire - Fri May 27, 7:20AM CDT
At present, the Biotech sphere is in a volatile state, but investors playing in this space know that volatility is what makes this industry interesting to consider. Here are this morning's featured companies on ActiveWallSt.com: Synta Pharmaceuticals Corp. (NASDAQ: SNTA), CTI BioPharma Corp. (NASDAQ: CTIC), Lpath Inc. (NASDAQ: LPTN), and Heat Biologics Inc. (NASDAQ: HTBX). Sign up now and gain access to the technical alerts for these stocks at:
HTBX: 1.34 (-0.02), SNTA: 0.34 (+0.07), CTIC: 0.39 (unch), LPTN: 2.35 (-0.02)
CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting
PR Newswire - Thu May 19, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced that data highlighting pacritinib, including additional safety and long-term follow up data from the Phase 3 PERSIST-1 clinical trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held June 3-7 in Chicago, IL. The abstracts are available on the ASCO website at www.asco.org. Details regarding the poster presentations, which will include additional data not available in the abstracts, follow.
CTIC: 0.39 (unch)
Preclinical Data Presented At AACR Indicate Pacritinib's Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment
PR Newswire - Wed Apr 20, 12:30AM CDT
CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) today announced findings from an investigator-sponsored preclinical study indicating that pacritinib, an inhibitor of JAK2, FLT3, IRAK1 and CSF1R, may be effective in reducing survival of myelofibrosis and acute myeloid leukemia (AML) repopulating cells. Further, this study also demonstrated that the combination of pacritinib at low nanomolar concentrations with dasatinib may eliminate self-renewing leukemia stem cells in blast crisis of chronic myeloid leukemia (CML) with minimal toxicity toward normal progenitors. In myeloid leukemias, these leukemic stem cells can evade initial treatment and hide within the bone marrow microenvironment, develop resistance to current therapies, self-renew and eventually cause relapse.
CTIC: 0.39 (unch)
SHAREHOLDER NOTICE: Rosen Law Firm Reminds CTI BioPharma Corp. Investors of Important April 11, 2016 Deadline in Class Action - CTIC
GlobeNewswire - Fri Apr 08, 5:30PM CDT
Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp. securities (NASDAQ:CTIC) pursuant to and/or traceable to the Registration Statement and Prospectus issued in connection with CTI BioPharma's September 24, 2015 Public Offering (the "offering"
and/or from March 4, 2014 through February 9, 2016, inclusive (the "Class Period" of the important April 11, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for CTI BioPharma investors under the federal securities laws. CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CTI BioPharma Corp. of Class Action Lawsuit and Upcoming Deadline - CTIC
ACCESSWIRE - Fri Apr 08, 11:54AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company"
(NASDAQ: CTIC) and certain of its officers. The class action, filed in United States District Court, Western District of Washington, and docketed under 16-cv-00216, is on behalf of a class consisting of all persons or entities who purchased CTI BioPharma securities: (1) pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's public offering on or about September 24, 2015 (the "Offering"; and/or (2) between March 4, 2014 and February 9, 2016, inclusive (the "Class Period". This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act". CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Imminent Lead Plaintiff Deadline
ACCESSWIRE - Fri Apr 08, 10:21AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CTI BioPharma Corp. ("CTI" or the "Company"
(NASDAQ: CTIC) of the April 11, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. CTIC: 0.39 (unch)
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against CTI BioPharma Corp. (CTIC) and Lead Plaintiff Deadline: April 11, 2016
ACCESSWIRE - Fri Apr 08, 9:01AM CDT
NEW YORK, NY / ACCESSWIRE / April 8, 2016 / Bronstein, Gewirtz & Grossman, LLC, notifies investors of class action against CTI BioPharma Corp. ("CTI" or the "Company"
(NASDAQ: CTIC). The class action has been filed in the United States District Court, Western District of Washington on behalf of a class consisting of all persons or entities who purchased CTI BioPharma securities: (1) pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's public offering on or about September 24, 2015 (the "Offering"; and/or (2) between March 4, 2014 and February 9, 2016, inclusive (the "Class Period". CTIC: 0.39 (unch)
UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action and a Lead Plaintiff Deadline of April 11, 2016
BusinessWire - Thu Apr 07, 11:13AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CTIC: 0.39 (unch)
April 11 Deadline Alert: GPM Reminds Investors of the Upcoming Lead Plaintiff Deadline in the Class Action Lawsuit against CTI BioPharma Corp. and Encourages Investors to Contact the Firm
BusinessWire - Wed Apr 06, 9:30AM CDT
Glancy Prongay & Murray LLP ("GPM"
reminds investors of the upcoming April 11, 2016 deadline to file a lead plaintiff motion in the class action filed by GPM on behalf of a class (the "Class" of investors who purchased or otherwise acquired CTI BioPharma Corp. ("CTI BioPharma" or the "Company" (NASDAQ: CTIC) securities pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement" issued in connection with the Company's public offering on or about September 24, 2015 (the "Offering"; and/or (2) between March 4, 2014 and February 9, 2016, inclusive (the "Class Period). Investors who suffered losses over $50,000 on their investment in CTI BioPharma securities are encouraged to contact GPM to discuss their legal rights in this class action. CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against CTI BioPharma Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Wed Apr 06, 4:45AM CDT
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company"
(Nasdaq: CTIC) concerning possible violations of federal securities laws between March 4, 2014 and February 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the April 11, 2016, lead plaintiff motion deadline. CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $50,000 Investing In CTI BioPharma Corp. To Contact The Firm Before Lead Plaintiff Deadline
PR Newswire - Tue Apr 05, 1:53PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in CTI BioPharma Corp. ("CTI" or the "Company"
(NASDAQ:CTIC) of the April 11, 2016 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers. CTIC: 0.39 (unch)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against CTI BioPharma Corp. and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm
BusinessWire - Tue Apr 05, 12:49PM CDT
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp. ("CTI BioPharma" or the "Company"
(Nasdaq: CTIC) concerning possible violations of federal securities laws between March 4, 2014 and February 9, 2016. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the April 11, 2016, lead plaintiff motion deadline. CTIC: 0.39 (unch)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2016 -- CTIC
Marketwired - Mon Apr 04, 9:47AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CTIC: 0.39 (unch)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of CTI BioPharma Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2016 - CTIC
GlobeNewswire - Thu Mar 31, 1:23PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
CTIC: 0.39 (unch)
